Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Opioid Epidemic Update (November/December) | 2021

View Archived Issues

Learning Objectives, Opioid Epidemic Update, CATR, November/December 2021

November 5, 2021

After reading these articles, you should be able to… Read More

Buprenorphine Treatment

November 5, 2021

Noah Capurso, MD

Buprenorphine is a first line medication for the treatment of opioid use disorder yet remains vastly under-prescribed. Here, Dr. Capurso reviews the pharmacologic principles relevant to buprenorphine prescribing and lays out how to start patients on the medication both in the clinic and at home. Read More

Drug Overdoses in the US: Trends and Prevention Strategies

November 5, 2021

Joshua Sharfstein, MD

Increases in drug overdose mortality continues unabated around the country driven by widespread availability of illicit fentanyl and methamphetamines. Dr. Sharfstein provides context to these concerning trends and discusses prevention and harm reduction strategies clinicians can implement for their patients. Read More

Suicide Safety Planning for the Patient with Addiction

November 5, 2021

Jessica Casella, LCSW

Addiction is a major risk factor for suicide. Here, we provide a practical guide to Safety Planning, an evidenced based approach for reducing suicide risk that can be implemented in a variety of clinical settings. Read More

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

November 5, 2021

Oluwole Jegede, MD, PhD

Avoiding buprenorphine induced withdrawal during induction can be particularly tricky for those using fentanyl. Researchers describe a novel induction dosing strategy that mitigates this risk. Read More

Buprenorphine Induction Without Withdrawal

November 5, 2021

David Moltz, MD.

Making the switch from full opioid agonist to buprenorphine usually involves a period of withdrawal prior to starting the medication. Here, researchers describe a method of switching from full to partial opioid agonist by using small “microdoses” in order to avoid withdrawal. Read More

Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?

November 5, 2021

Gregory Lande, MD.

Buprenorphine and long acting injectable naltrexone are both effective for the treatment of opioid use disorder; however, until now, we had little data to predict which patients would do better on which medications. Here, researchers identify patient characteristics predictive of success on buprenorphine versus naltrexone. Read More